Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12,383 stopped studies mapped to Malignant Neoplasm and descendants · 89% state a reason
Over the 12,383 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After… | Phase 1 | withdrawn | May 20, 2009 | Millennium Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00452140 | Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast… | Phase 2 | terminated | Mar 27, 2007 | Neovii Biotech | company focus on other projects | Sponsor / business decision |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in… | Phase 1 | terminated | Oct 15, 2007 | Sanofi | due to absence of evidence of clinical activity up to toxic doses | Other (stated, no rule matched) |
| NCT00119600 | A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in… | Phase 1 / Phase 2 | terminated | Jul 14, 2005 | Amgen | not stated | Not stated |
| NCT00733798 | A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant… | Phase 1 / Phase 2 | terminated | Aug 13, 2008 | TransMolecular | For Strategic Reasons | Sponsor / business decision |
| NCT00209014 | Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and… | Phase 2 | terminated | Sep 21, 2005 | Emory University | Celgene unable to continue funds. | Funding |
| NCT00435578 | Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell… | Phase 2 | terminated | Feb 15, 2007 | Threshold Pharmaceuticals | not stated | Not stated |
| NCT00888810 | Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer(TOPO-LAPA) | Phase 2 | terminated | Apr 28, 2009 | Centre Francois Baclesse | lack of efficacy (intermediate analysis) | Efficacy / futility |
| NCT00547404 | Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma | Phase 1 | withdrawn | Oct 22, 2007 | Piramal Enterprises Limited | Not to expose the patients to subtherapeutic dose | Other (stated, no rule matched) |
| NCT00584207 | Radiofrequency Ablation of Uterine Fibroids | Early Phase 1 | terminated | Jan 2, 2008 | University of California, Davis | Unsufficient referrals for recruitment | Enrollment / accrual |
| NCT00241462 | Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients(FORUM) | — | terminated | Oct 19, 2005 | AstraZeneca | Due to poor patient enrollment | Enrollment / accrual |
| NCT00491738 | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in… | Phase 2 | terminated | Jun 26, 2007 | Genentech, Inc. | Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly… | Other (stated, no rule matched) |
| NCT00083564 | Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone,… | Phase 3 | terminated | May 28, 2004 | Poniard Pharmaceuticals | For business reasons | Sponsor / business decision |
| NCT00459823 | A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28… | Phase 1 | suspended | Apr 13, 2007 | Eisai Limited | not stated | Not stated |
| NCT00605800 | Bone Marrow Derived Adult Liver Stem Cell Recruitment After Major Liver Resections:… | — | withdrawn | Jan 31, 2008 | Memorial Sloan Kettering Cancer Center | Study was closed due to logistical issues. | Other (stated, no rule matched) |
| NCT00174369 | MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer | Phase 2 | terminated | Sep 15, 2005 | Pfizer | Terminated \[See Detailed Description for Termination Reason.\] | Other (stated, no rule matched) |
| NCT00272415 | A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety,… | Phase 1 | terminated | Jan 6, 2006 | Genentech, Inc. | not stated | Not stated |
| NCT00540332 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally… | Phase 1 / Phase 2 | withdrawn | Oct 8, 2007 | Swedish Orphan Biovitrum | The 20070201 study was terminated based on evaluation of Palifermin solid tumor data. | Other (stated, no rule matched) |
| NCT00585845 | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced… | Phase 1 | terminated | Jan 3, 2008 | Anza Therapeutics, Inc. | not stated | Not stated |
| NCT00209612 | Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of… | Phase 1 / Phase 2 | withdrawn | Sep 21, 2005 | Hokkaido Gastrointestinal Cancer Study Group | due to strong side effect | Other (stated, no rule matched) |
| NCT00129870 | CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in… | Phase 4 | terminated | Aug 12, 2005 | Sanofi | Unplanned interim analysis by DSMB indicated possible reduced response rate with the addition of… | Efficacy / futility |
| NCT00461929 | Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on…(GIST) | Phase 4 | terminated | Apr 18, 2007 | University Health Network, Toronto | study terminated 12Feb09 due to low recruitment | Enrollment / accrual |
| NCT00327093 | Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and… | Phase 4 | terminated | May 18, 2006 | Hospices Civils de Lyon | The scientific commitee decided to stop the inclusions and exploit the results. | Other (stated, no rule matched) |
| NCT00304200 | Temodar and Sutent as Therapy for Melanoma | Phase 1 / Phase 2 | terminated | Mar 17, 2006 | Northern California Melanoma Center | Funding was inadequate to continue; Companies requested closure. | Funding |
| NCT00499499 | A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days… | Phase 1 | suspended | Jul 11, 2007 | Eisai Inc. | not stated | Not stated |
| NCT00503321 | Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma(eNCIT-Japan) | Phase 2 / Phase 3 | terminated | Jul 18, 2007 | Eastern Network of Cancer Immunological Therapy, Japan | Patients' enrollment was not sufficient. | Enrollment / accrual |
| NCT00365222 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | Phase 2 | terminated | Aug 17, 2006 | H. Lee Moffitt Cancer Center and Research Institute | IRB Study Closure | Other (stated, no rule matched) |
| NCT00039754 | A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With… | Phase 1 / Phase 2 | terminated | Jun 11, 2002 | Poniard Pharmaceuticals | business reasons | Sponsor / business decision |
| NCT00090025 | XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary… | Phase 3 | terminated | Aug 23, 2004 | Helsinn Healthcare SA | Futility reasons after Independent Data Monitoring Committee interim analysis | Efficacy / futility |
| NCT00637364 | High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain(HIFU Pancreas) | Phase 1 / Phase 2 | suspended | Mar 18, 2008 | CMED HIFU Development Corporation | Sponsor is not proceeding with USA human trial at this time | Other (stated, no rule matched) |
| NCT00083447 | Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With… | Phase 3 | withdrawn | May 26, 2004 | Xenova Biomedix | This study has been withdrawn because the drug would not meet trial criteria for efficacy | Efficacy / futility |
| NCT00810706 | Adjuvant Post-Tamoxifen Exemestane Trial(ATENA) | Phase 3 | terminated | Dec 18, 2008 | Hellenic Breast Surgeons Society | Publication of MA17 results (similar trial in the extented adjuvant setting with letrozole) | Other (stated, no rule matched) |
| NCT00319683 | A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic… | Phase 1 / Phase 2 | terminated | Apr 27, 2006 | Adherex Technologies, Inc. | Lack of funds | Funding |
| NCT00165633 | A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of… | Phase 2 / Phase 3 | terminated | Sep 14, 2005 | Eisai Limited | not stated | Not stated |
| NCT00493857 | Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer | Phase 2 | terminated | Jun 28, 2007 | YM BioSciences | Cohort 2 not going forward. Manadate changes in Company | Sponsor / business decision |
| NCT00753480 | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial… | Phase 1 | suspended | Sep 16, 2008 | Genentech, Inc. | not stated | Not stated |
| NCT00089856 | GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic… | Phase 3 | terminated | Aug 18, 2004 | Cell Genesys | Based on futility analysis showing \<30% chance of meeting primary endpoint. | Efficacy / futility |
| NCT00485966 | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell… | Phase 2 | withdrawn | Jun 13, 2007 | Cylene Pharmaceuticals | This study was withdrawn prior to patient enrollment | Enrollment / accrual |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute… | Phase 2 | withdrawn | Jan 15, 2008 | University of Cincinnati | Principal Investigator resigned position with the University of Cincinnati, closing study at this… | Investigator |
| NCT00352742 | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jul 17, 2006 | Attenuon | not stated | Not stated |
| NCT00303615 | Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-)… | Phase 2 | terminated | Mar 17, 2006 | Legacy Health System | Low accrural | Enrollment / accrual |
| NCT00156260 | Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage | — | terminated | Sep 12, 2005 | University of Michigan Rogel Cancer Center | not stated | Not stated |
| NCT00172367 | Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma | Phase 2 | withdrawn | Sep 15, 2005 | National Taiwan University Hospital | This study was for National Science Council project. The study was not funded, so the study was… | Funding |
| NCT00133224 | Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in… | Phase 3 | terminated | Aug 23, 2005 | Cell Genesys | Accrual and treatment with CG1940/CG8711 stopped due to IDMC recommendation. | Enrollment / accrual |
| NCT00380835 | Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer | Phase 2 | withdrawn | Sep 27, 2006 | Celgene Corporation | Study Never Initiated | Other (stated, no rule matched) |
| NCT00104130 | Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer | Phase 2 | terminated | Feb 24, 2005 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00538096 | A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma | Phase 1 | withdrawn | Oct 2, 2007 | MedImmune LLC | Replacing this trial with a new trial. | Other (stated, no rule matched) |
| NCT00676871 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous… | Phase 1 / Phase 2 | withdrawn | May 13, 2008 | MedImmune LLC | Replacing this trial with a new trial. | Other (stated, no rule matched) |
| NCT00415155 | A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | withdrawn | Dec 22, 2006 | Eli Lilly and Company | Trial cancelled | Other (stated, no rule matched) |
| NCT00351195 | Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | terminated | Jul 12, 2006 | Rigshospitalet, Denmark | Did not meet the criteria for continuation to second stage | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 20, 2009source: clinicaltrials